Compare Amphastar Pharmaceuticals Inc (AMPH) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Kroger Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Kroger Co trades at $60.86 (market cap $37.09B). The key difference: Kroger Co is far larger — about 44.9× Amphastar Pharmaceuticals Inc's market cap, and Kroger Co pays a 2.38% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KR | |
|---|---|---|
Market Cap | $826.08M | $37.09B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $75.60 |
52-Week Low | $16.87 | $55.53 |
Enterprise Value | $1.22B | $57.18B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Kroger (KR) trades at $60.54, up 1.14% today, near the analyst consensus price target of $68.63. The stock shows bullish technical signals despite a mixed earnings history, with recent beats in Q3 and Q4 2025 but a miss in Q1 2026. Fundamentals reveal a low P/S ratio of 0.26 and steady dividends, while the recent $1.65 billion acquisition of Giant Eagle aims to expand Midwest presence amid intense grocery competition.
KR offers value with solid cash flow and growth initiatives, but risks include margin pressure from industry competition and integration challenges from acquisitions. Analyst sentiment is positive with 48% buy ratings, supporting a cautious bullish outlook for patient investors focused on long-term retail consolidation benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
